{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:03:24Z","timestamp":1792411404384,"version":"4.4.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The benefit\u2013risk of coronavirus disease 2019 (COVID-19) vaccination in children remains unclear. We evaluated the effects of mRNA vaccines on COVID-19 hospitalization, pericarditis\/myocarditis, and MISC-C in children 6\u201317 years old.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The Madrid Health System Registry was linked with 3 databases of the Madrilenian Health Service (primary care, hospital admissions, and pharmacy) to identify eligible children 6\u201317 years of age. We matched children receiving an mRNA vaccine with 5 controls and compared 240-day risks for vaccines and controls, with bootstrapping to obtain 95% confidence intervals. Effectiveness was defined as 1 minus the risk ratio. All analyses were conducted by age group (6\u201311 and 12\u201317 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In 183,273 vaccinated and 916,365 controls 6\u201311 years old, the estimated risk difference (95% CI) of COVID-19 hospitalization was \u22121.2 per 100,000 (\u22126.6 to 4.0) for vaccinated versus controls; effectiveness 9.0% (\u221236 to 49). The risk difference of multisystem inflammatory syndrome in children was \u22121.4 per 100,000 (\u22124.7 to 2.3); effectiveness 27.0% (\u221254 to 76). No cases of myocarditis or pericarditis occurred. In 277,561 vaccinated and 1,387,805 controls 12\u201317 years old, the estimated risk difference of COVID-19 hospitalization was \u22125.3 per 100,000 (\u22129.0 to \u22122.0); effectiveness 45% (18\u201372). The risk difference of multisystem inflammatory syndrome in children was \u22121.3 per 100,000 (\u22123.0 to 0.8), effectiveness 42% (\u221231 to 83). The risk ratio of pericarditis\/myocarditis for vaccinated versus controls was 1.09 (0.60\u20131.70).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The risks and benefits of COVID-19 vaccines were small in a general population of children 6\u201317 years of age.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005109","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T05:00:20Z","timestamp":1765861220000},"page":"e121-e124","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and Safety of COVID-19 mRNA Vaccines in Children 6\u201317 Years Old: A Population-based Study in Madrid"],"prefix":"10.1097","volume":"45","author":[{"given":"Miguel A.","family":"Hern\u00e1n","sequence":"first","affiliation":[{"name":"CAUSALab, Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"\u00c1lvaro-Meca","sequence":"additional","affiliation":[{"name":"Centro de Investigacio\u0301n Biome\u0301dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Medicina Preventiva y Salud P\u00fablica, Universidad Rey Juan Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Calvo-Alc\u00e1ntara","sequence":"additional","affiliation":[{"name":"Subdirecci\u00f3n General de Farmacia y Productos Sanitarios, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Navarro G\u00f3mez","sequence":"additional","affiliation":[{"name":"Centro de Investigacio\u0301n Biome\u0301dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Pediatric Infectious Diseases, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"},{"name":"Universidad Complutense de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 T.","family":"Ramos","sequence":"additional","affiliation":[{"name":"Centro de Investigacio\u0301n Biome\u0301dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Universidad Complutense de Madrid, Madrid, Spain"},{"name":"Pediatric Infectious Diseases, Instituto de Investigaci\u00f3n Sanitaria (i+12), Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 C.","family":"Est\u00e9vez","sequence":"additional","affiliation":[{"name":"Gerencia Asistencial de Atenci\u00f3n Primaria, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Basanta","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Salud Digital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Gerencia Asistencial de Atenci\u00f3n Primaria, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel L.","family":"Mat\u00e1ix","sequence":"additional","affiliation":[{"name":"Subdirecci\u00f3n General de Farmacia y Productos Sanitarios, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Cosano","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aura P.","family":"Silva","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Salas","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Arribas","sequence":"additional","affiliation":[{"name":"Centro de Investigacio\u0301n Biome\u0301dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Medicina Interna, Hospital Universitario La Paz, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz (IdiPAZ), Madrid, Spain"},{"name":"Universidad Aut\u00f3noma de Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Molero","sequence":"additional","affiliation":[{"name":"Centro de Salud San Andr\u00e9s, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Berenguer","sequence":"additional","affiliation":[{"name":"Centro de Investigacio\u0301n Biome\u0301dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"},{"name":"Infectious Diseases, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"R1-20260310","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMp2507404","article-title":"The role of public health agencies in creating vaccine policy.","volume":"393","author":"Marks","year":"2025","journal-title":"N Engl J Med"},{"key":"R2-20260310","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(22)01245-4","article-title":"COVID-19 vaccination for children aged 5-11 years.","volume":"400","author":"Ladhani","year":"2022","journal-title":"Lancet"},{"key":"R3-20260310","doi-asserted-by":"crossref","first-page":"225","DOI":"10.15585\/mmwr.mm7310a2","article-title":"Notes from the field: surveillance for multisystem inflammatory syndrome in children\u2014United States, 2023.","volume":"73","author":"Yousaf","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R4-20260310","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/jama.2025.10658","article-title":"Changed recommendations for COVID-19 vaccines for children and pregnant women: a failure of process, policy, and science.","volume":"334","author":"Gostin","year":"2025","journal-title":"JAMA"},{"key":"R5-20260310","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJMoa2205011","article-title":"BNT162b2 vaccine effectiveness against omicron in children 5 to 11 years of age.","volume":"387","author":"Cohen-Stavi","year":"2022","journal-title":"N Engl J Med"},{"key":"R6-20260310","first-page":"209","article-title":"OpenSAFELY: effectiveness of COVID-19 vaccination in children and adolescents.","volume":"393","author":"Andrews","year":"2025","journal-title":"Epidemiology"},{"key":"R7-20260310","doi-asserted-by":"crossref","first-page":"ofad635","DOI":"10.1093\/ofid\/ofad635","article-title":"Three years of the coronavirus disease 2019 pandemic in a European Region: a population-based longitudinal assessment in Madrid between 2020 and 2022.","volume":"11","author":"Berenguer","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"R8-20260310","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting.","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"R9-20260310","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0140-6736(22)01185-0","article-title":"Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.","volume":"400","author":"Sacco","year":"2022","journal-title":"Lancet"},{"key":"R10-20260310","doi-asserted-by":"crossref","first-page":"126539","DOI":"10.1016\/j.vaccine.2024.126539","article-title":"COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: a Canadian Immunization Research Network (CIRN) study.","volume":"44","author":"Piche-Renaud","year":"2025","journal-title":"Vaccine"},{"key":"R11-20260310","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S2352-4642(23)00078-0","article-title":"Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis.","volume":"7","author":"Piechotta","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"R12-20260310","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1007\/s00431-024-05586-4","article-title":"Multisystemic inflammatory syndrome in children and the BNT162b2 vaccine: a nationwide cohort study.","volume":"183","author":"Schwartz","year":"2024","journal-title":"Eur J Pediatr"},{"key":"R13-20260310","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S2352-4642(22)00100-6","article-title":"Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study.","volume":"6","author":"Nygaard","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"R14-20260310","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1093\/cid\/ciac637","article-title":"BNT162b2 mRNA vaccination against coronavirus disease 2019 is associated with a decreased likelihood of multisystem inflammatory syndrome in children aged 5-18 years\u2014United States, July 2021\u2013 April 2022.","volume":"76","author":"Zambrano","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R15-20260310","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jama.2021.23262","article-title":"multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France.","volume":"327","author":"Levy","year":"2022","journal-title":"JAMA"},{"key":"R16-20260310","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.15585\/mmwr.mm7036e2","article-title":"Hospitalizations associated with COVID-19 among children and adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021.","volume":"70","author":"Delahoy","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R17-20260310","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.15585\/mmwr.mm7036e1","article-title":"Trends in COVID-19 cases, emergency department visits, and hospital admissions among children and adolescents aged 0-17 years\u2014United States, August 2020\u2013August 2021.","volume":"70","author":"Siegel","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R18-20260310","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.15585\/mmwr.mm6932e3","article-title":"Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020.","volume":"69","author":"Kim","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R20-20260310","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1542\/hpeds.2021-006001","article-title":"\u201cFor COVID\u201d or \u201cWith COVID\u201d: classification of SARS-CoV-2 hospitalizations in children.","volume":"11","author":"Kushner","year":"2021","journal-title":"Hosp Pediatr"},{"key":"R21-20260310","first-page":"607","article-title":"Myocarditis and pericarditis following mRNA COVID-19 vaccination: what do we know so far?","volume":"8","author":"Das","year":"2021","journal-title":"Children (Basel)"},{"key":"R22-20260310","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jinf.2021.11.011","article-title":"Persistent symptoms following SARS-CoV-2 infection amongst children and young people: a meta-analysis of controlled and uncontrolled studies.","volume":"84","author":"Behnood","year":"2022","journal-title":"J Infect"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:01:46Z","timestamp":1773115306000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005109","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}